Article Details

Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat

Retrieved on: 2022-10-17 11:35:11

Tags for this article:

Click the tags to see associated articles and topics

Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat. View article details on hiswai:

Excerpt

The U.S. Food and Drug Administration (FDA) granted fast track designation to Mereo BioPharma alvelestat (MPH-966) to treat Alpha-1 Antitrypsin ...

Article found on: seekingalpha.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up